Mirae Asset Global Investments Co., Ltd. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2021. The put-call ratio across all filers is 8.37 and the average weighting 0.1%.

Quarter-by-quarter ownership
Mirae Asset Global Investments Co., Ltd. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$7,521,009
-15.2%
210,968
+9.8%
0.02%
-10.5%
Q2 2023$8,865,510
-5.2%
192,123
-17.6%
0.02%
-13.6%
Q1 2023$9,349,556
-10.2%
233,156
+3.8%
0.02%
-18.5%
Q4 2022$10,409,285
+89.7%
224,677
+69.6%
0.03%
+80.0%
Q3 2022$5,487,000
-28.2%
132,492
+3.4%
0.02%
-21.1%
Q2 2022$7,645,000
-61.6%
128,159
-53.2%
0.02%
-9.5%
Q1 2022$19,884,000
+47.1%
273,812
+70.4%
0.02%
-27.6%
Q4 2021$13,515,000
+21.4%
160,727
+30.2%
0.03%
+3.6%
Q3 2021$11,131,000
+14.0%
123,407
+20.5%
0.03%
+3.7%
Q2 2021$9,764,000
-2.8%
102,395
+16.0%
0.03%
-22.9%
Q1 2021$10,049,000
+33.0%
88,261
+61.7%
0.04%
+25.0%
Q4 2020$7,558,000
+107.4%
54,598
+23.1%
0.03%
+55.6%
Q3 2020$3,644,000
+47.2%
44,336
+40.1%
0.02%
+20.0%
Q2 2020$2,476,000
+162.6%
31,645
+49.0%
0.02%
+114.3%
Q1 2020$943,000
+16.3%
21,242
+11.8%
0.01%
+40.0%
Q4 2019$811,000
+75.2%
18,994
+75.7%
0.01%
+66.7%
Q3 2019$463,000
+92.1%
10,809
+185.4%
0.00%
+50.0%
Q2 2019$241,0003,7870.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2021
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders